text: , there were 281 marketed orphan drugs and more than 400 orphan-designated drugs in clinical trials. More than 60% of orphan drugs were biologics. The U.S. dominated development of orphan drugs, with more than 300 trials, followed by Europe. Cancer treatment was the indication in more than 30% of orphan drug trials.
  * Number of orphan drugs in clinical trials: 40
  * Number of orphan drugs in phase 2 trial: 231
  * Number of orphan drugs in U.S. clinical trials: 350 in the pipeline from research until registration